Table 6 Subgroup analysis of the association between GNRI and in-hospital mortality in patients with sepsis.
From: Prognostic nutritional indices predict 60 day mortality in ICU patients with sepsis
Variable | N (%) | Levels | HR (95% CI) | P value | P for interaction |
|---|---|---|---|---|---|
Age | 0.601 | ||||
> 65 | 781 (47.4) | Q1 | Reference | ||
Q2 | 0.8 (0.57–1.12) | 0.194 | |||
Q3 | 0.61 (0.4–0.91) | 0.017 | |||
≤ 65 | 868 (52.6) | Q1 | Reference | ||
Q2 | 0.82 (0.58–1.16) | 0.264 | |||
Q3 | 0.75 (0.53–1.07) | 0.109 | |||
Gender | 0.921 | ||||
F | 656 (39.78) | Q1 | Reference | ||
Q2 | 0.82 (0.56–1.21) | 0.315 | |||
Q3 | 0.65 (0.43–0.96) | 0.031 | |||
M | 993 (60.22) | Q1 | Reference | ||
Q2 | 0.78 (0.57–1.07) | 0.129 | |||
Q3 | 0.69 (0.49–0.98) | 0.036 | |||
Race | 0.103 | ||||
Black | 167 (10.13) | Q1 | Reference | ||
Q2 | 1.22 (0.56–2.67) | 0.614 | |||
Q3 | 0.18 (0.04–0.81) | 0.025 | |||
Others | 454 (27.53) | Q1 | Reference | ||
Q2 | 0.81 (0.54–1.22) | 0.322 | |||
Q3 | 0.73 (0.48–1.11) | 0.137 | |||
White | 1028 (62.34) | Q1 | Reference | ||
Q2 | 0.76 (0.55–1.07) | 0.113 | |||
Q3 | 0.72 (0.51–1.02) | 0.066 | |||
Marital status | 0.134 | ||||
Divorced | 120 (7.28) | Q1 | Reference | ||
Q2 | 0.22 (0.06–0.77) | 0.017 | |||
Q3 | 0.37 (0.13–1.05) | 0.062 | |||
Married | 714 (43.30) | Q1 | Reference | ||
Q2 | 0.86 (0.58–1.28) | 0.466 | |||
Q3 | 0.75 (0.5–1.13) | 0.168 | |||
Others | 222 (13.46) | Q1 | Reference | ||
Q2 | 0.66 (0.4–1.06) | 0.088 | |||
Q3 | 0.91 (0.53–1.54) | 0.719 | |||
Single | 468 (28.38) | Q1 | Reference | ||
Q2 | 1.07 (0.64–1.79) | 0.809 | |||
Q3 | 0.83 (0.48–1.43) | 0.496 | |||
Widowed | 125 (7.58) | Q1 | Reference | ||
Q2 | 0.9 (0.35–2.3) | 0.832 | |||
Q3 | 0.31 (0.09–1.05) | 0.059 | |||
Myocardial infarction | 0.424 | ||||
No | 1409 (85.45) | Q1 | Reference | ||
Q2 | 0.84 (0.64–1.1) | 0.214 | |||
Q3 | 0.67 (0.5–0.89) | 0.006 | |||
Yes | 240 (14.55) | Q1 | Reference | ||
Q2 | 0.63 (0.35–1.15) | 0.136 | |||
Q3 | 0.76 (0.42–1.4) | 0.382 | |||
CHF | 0.156 | ||||
No | 1263 (76.59) | Q1 | Reference | ||
Q2 | 0.85 (0.64–1.13) | 0.26 | |||
Q3 | 0.77 (0.57–1.04) | 0.088 | |||
Yes | 386 (23.41) | Q1 | Reference | ||
Q2 | 0.68 (0.43–1.09) | 0.109 | |||
Q3 | 0.42 (0.24–0.72) | 0.002 | |||
Diabetes | 0.049 | ||||
No | 1317 (79.87) | Q1 | Reference | ||
Q2 | 0.78 (0.6–1.03) | 0.082 | |||
Q3 | 0.78 (0.59–1.04) | 0.092 | |||
Yes | 332 (20.13) | Q1 | Reference | ||
Q2 | 0.85 (0.49–1.47) | 0.555 | |||
Q3 | 0.37 (0.19–0.72) | 0.003 | |||
Hypertension | 0.464 | ||||
No | 794 (48.15) | Q1 | Reference | ||
Q2 | 0.76 (0.56–1.04) | 0.09 | |||
Q3 | 0.75 (0.54–1.04) | 0.082 | |||
Yes | 855 (51.85) | Q1 | Reference | ||
Q2 | 0.94 (0.63–1.41) | 0.764 | |||
Q3 | 0.67 (0.43–1.04) | 0.072 | |||
Cerebrovascular disease | 0.721 | ||||
No | 1473 (89.33) | Q1 | Reference | ||
Q2 | 0.8 (0.61–1.04) | 0.09 | |||
Q3 | 0.65 (0.49–0.86) | 0.003 | |||
Yes | 176 (10.67) | Q1 | Reference | ||
Q2 | 0.81 (0.4–1.61) | 0.541 | |||
Q3 | 0.87 (0.41–1.86) | 0.728 | |||
Antibiotics | 0.129 | ||||
Beta-lactams | 211 (12.80) | Q1 | Reference | ||
Q2 | 0.76 (0.41–1.39) | 0.372 | |||
Q3 | 0.75 (0.4–1.4) | 0.366 | |||
Glycopeptides | 435 (26.38) | Q1 | Reference | ||
Q2 | 1.09 (0.7–1.71) | 0.699 | |||
Q3 | 0.85 (0.52–1.39) | 0.521 | |||
Macrolides | 54 (3.27) | Q1 | Reference | ||
Q2 | 5.15 (0.91–29.2) | 0.064 | |||
Q3 | 0.63 (0.05–7.42) | 0.713 | |||
Others | 949 (57.55) | Q1 | Reference | ||
Q2 | 0.62 (0.44–0.88) | 0.007 | |||
Q3 | 0.56 (0.39–0.81) | 0.002 | |||
Glucocorticoids | 0.939 | ||||
No | 844 (51.18) | Q1 | Reference | ||
Q2 | 0.81 (0.56–1.17) | 0.267 | |||
Q3 | 0.64 (0.43–0.96) | 0.03 | |||
Yes | 805 (48.82) | Q1 | Reference | ||
Q2 | 0.78 (0.56–1.08) | 0.131 | |||
Q3 | 0.69 (0.49–0.97) | 0.033 |
